Showing results (681-690 of 735) with videos related to
Sort By:
Pageof 74
Nature Medicine|May 29, 2023
Pan-cancer T cell atlas links a cellular stress response state to immunotherapy resistanceYanshuo Chu, Enyu Dai, Yating Li, et al.Science (New York, N.Y.)|October 11, 2014
Spatial and temporal diversity in genomic instability processes defines lung cancer evolutionElza C de Bruin, Nicholas McGranahan, Richard Mitter, et al.The New England Journal of Medicine|June 2, 2015
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated MelanomaJames Larkin, Vanna Chiarion-Sileni, Rene Gonzalez, et al.Journal of Translational Medicine|October 29, 2014
Future perspectives in melanoma research: meeting report from the "Melanoma Bridge", Napoli, December 5th-8th 2013Paolo A Ascierto, Antonio M Grimaldi, Ana Carrizosa Anderson, et al.Cell|November 8, 2025
Longitudinal ultrasensitive ctDNA monitoring for high-resolution lung cancer risk predictionJames R M Black, Takahiro Karasaki, Charles W Abbott, et al.Cancer Discovery|July 22, 2020
Immune Surveillance in Clinical Regression of Preinvasive Squamous Cell Lung CancerAdam Pennycuick, Vitor H Teixeira, Khalid AbdulJabbar, et al.Nature Communications|May 31, 2024
Representation of genomic intratumor heterogeneity in multi-region non-small cell lung cancer patient-derived xenograft modelsRobert E Hynds, Ariana Huebner, David R Pearce, et al.The Lancet. Oncology|April 15, 2021
Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trialAlexander M M Eggermont, Christian U Blank, Mario Mandalà, et al.The New England Journal of Medicine|September 16, 2024
Final, 10-Year Outcomes with Nivolumab plus Ipilimumab in Advanced MelanomaJedd D Wolchok, Vanna Chiarion-Sileni, Piotr Rutkowski, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 18, 2020
Longer Follow-Up Confirms Recurrence-Free Survival Benefit of Adjuvant Pembrolizumab in High-Risk Stage III Melanoma: Updated Results From the EORTC 1325-MG/KEYNOTE-054 TrialAlexander M M Eggermont, Christian U Blank, Mario Mandala, et al.Pageof 74